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ABSTRACT
Objectives: To analyse the temporal and geographical
diffusion of antivascular endothelial growth factor
(anti-VEGF) interventions, and its determinants in a
National Health System (NHS).
Setting: NHS Portuguese hospitals.
Participants: All inpatient and day cases related to
eye diseases at all Portuguese public hospitals for the
period 2002–2012 were selected on the basis of four
International Classification of Diseases 9th revision,
Clinical Modification (ICD-9-CM) codes for procedures:
1474, 1475, 1479 and 149.
Primary and secondary outcome measures: We
measured anti-VEGF treatment rates by year and
county. The determinants of the geographical diffusion
were investigated using generalised linear modelling.
Results: We analysed all hospital discharges from all
NHS hospitals in Portugal (98 408 hospital discharges
corresponding to 57 984 patients). National rates of
hospitals episodes for the codes for procedures used
were low before anti-VEGF approval in 2007 (less than
12% of hospital discharges). Between 2007 and 2012,
the rates of hospital episodes related to the
introduction of anti-VEGF injections increased by 27%
per year. Patients from areas without ophthalmology
departments received fewer treatments than those from
areas with ophthalmology departments. The availability
of an ophthalmology department in the county
increased the rates of hospital episodes by 243%, and
a 100-persons greater density per km2 raised the rates
by 11%.
Conclusions: Our study shows a large but unequal
diffusion of anti-VEGF treatments despite the universal
coverage and very low copayments. The technological
innovation in ophthalmology may thus produce
unexpected inequalities related to financial constraints
unless the implementation of innovative techniques is
planned and regulated.
INTRODUCTION
Age-related macular degeneration (AMD) is a
chronic, progressive disease and the most
common cause of visual impairment in devel-
oped countries in patients older than
65 years.1–7 AMD requires lifelong observation
and interventions.8 AMD can be divided into
two stages: early AMD, characterised by
subretinal pigmented epithelium deposits
(drusen) and pigmentary changes and
advanced AMD.5 Advanced AMD has atrophic
and neovascular forms. Although neovascular
AMD comprises only 10% of the burden of
the disease, it is responsible for 90% of severe
vision loss.1 9–12 Vision loss leads to reduced
quality of life and autonomy, and is associated
with large costs for health systems and the
society.10 13–15
Before the introduction of antivascular
endothelial growth factor (anti-VEGF) treat-
ments, AMD was largely untreatable.16
Anti-VEGF therapy for neovascular AMD has
substantially changed the management of
the disease.16 17 These drugs are injected
into the vitreous chamber to reduce neovas-
cular formation in the macula.2 Currently
the most common anti-VEGF therapies in
Portugal are: (1) Ranibizumab (Lucentis,
Novartis) which was licensed for the treat-
ment of neovascular AMD by the Food and
Drug Administration (FDA) in 2006 and by
the European Medicines Agency (EMA) in
2007. In Portugal, ranibizumab has been
covered by the National Health Service
(NHS) since 2008. Ranibizumab is the most
Strengths and limitations of this study
▪ A unique analysis of temporal and geograph-
ical patterns of the diffusion of antivascular
endothelial growth factor (anti-VEGF) treat-
ments for eye diseases during one decade
including all public hospitals in a National
Health System.
▪ Results raise awareness to inequalities in eye
care that can lead to irreversible sight loss
caused by treatable eye diseases.
▪ The study points some determinants that can be
modified to ensure that all patients with progres-
sive eye conditions are treated equally.
▪ The lack of specific codes for anti-VEGF
injections.
▪ The exclusion of the activity in the private health
sector.
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widely used approved anti-VEGF drug in Europe;1 3 18
(2) Bevacizumab (Avastin, Roche) was licensed in 2004
by the FDA, and by EMA in 2005 for the treatment of
metastatic colorectal cancer. It has been widely used for
the treatment of neovascular AMD as an off-label alter-
native;16 (3) Pegaptanib sodium (Macugen, Eyetech/
Pfizer) was approved by FDA in 2004 and by EMA in
2006 for the treatment of neovascular AMD. It is less
commonly used in clinical practice as it is not as effect-
ive as ranibizumab or bevacizumab.2 19 In Portugal this
therapy was approved but not marketed; (4) Aflibercept
(Eylea, Bayer) was approved for wet AMD treatment by
FDA in 2011 and by the EMA in 2012. Aflibercept is
covered by the Portuguese NHS since 2014.
Several clinical trials have shown that intravitreal injec-
tions prevent vision loss in the majority of patients and
in some cases, significantly improved vision16 20–22 with
low numbers of serious adverse effects.8 Subsequently,
anti-VEGF therapy has become the standard clinical
option to treat patients with AMD.18 20 21 In 2011,
anti-VEGF therapy was also introduced as treatment for
diabetic macular oedema and central retinal vein
occlusion.1 18 23
New therapies, such as anti-VEGF injections,
improve the clinical course of diseases but represent
substantial expenditures for healthcare systems.24 To
face rising costs of healthcare, copayments have been
introduced during the period of this study in public
Portuguese hospitals. If not exempt due to special cir-
cumstances, such as being disabled, patients receiving
anti-VEGF injections have to pay typically €7.5 per
appointment with their physician at the hospital. In
the context of economic recession and tight public
budgets, the introduction and diffusion of these treat-
ments can face substantial barriers.25 Despite the
strong equity commitment of the Portuguese NHS,
one of the expected barriers is likely to be geograph-
ical due to unequal distribution of resources across
areas.
The aim of this study was to examine the diffusion of
anti-VEGF drugs in the Portuguese NHS by analysing
the temporal and geographical diffusion patterns and its
determinants. We conducted a longitudinal study in
order to measure the evolution of hospital episodes
related to anti-VEGF treatments per county from 2002 to
2012.
METHODS
Data sources and extraction strategies
We used an administrative database that includes demo-
graphic, administrative and clinical information from all
inpatient and day case episodes performed at all
Portuguese NHS hospitals during the years 2002–2012.
Authorisation to use these information was obtained
by the Institutional Review Board (IRB) from Escola
Nacional de Saúde Pública/Universidade Nova de
Lisboa. In order to select the episodes related to
intravitreal injections for anti-VEGF treatments, we used
the following International Classification of Diseases 9th
revision, Clinical Modification (ICD-9-CM) codes for
procedures: 1474, 1475, 1479, 149. These codes have
been commonly used in the literature but they are
likely to capture other treatments such as injectable
antibiotics or corticosteroids.1 Cases were excluded even
if the diagnosis was likely to be associated with
anti-VEGF treatment but the code of procedure was
outside the selected group specified above. For
example, for the five diagnoses shown in figure 2, there
were 13 750 cases excluded from further analysis due to
this filter. Effects to our estimation caused by the poor
specificity of the code were reduced using two methods:
(1) years 2002–2006 were included as baseline as before
2006 intravitreal anti-VEGF treatments for ophthalmo-
logical use were not licensed; and (2) we crossed infor-
mation of age with principal diagnosis. Baseline years
provide the picture of the number of cases associated
with the codes but not related with anti-VEGF treat-
ments. We considered that AMD only affects people
in the age range 50–59 years or above,26 and anti-VEGF
are used for specific diagnosis such as AMD or
diabetic macular oedema. Online supplementary tables
S1 and S2 show how this information was used in our
methods. For the period studied, the only approved
anti-VEGF drugs for use in public hospitals were
Ranibizumab (Lucentis, Novartis) and Bevacizumab
(Avastin).
We used the indicators given below:
▸ The absolute values of the number of hospital epi-
sodes per year. Episodes were then disaggregated by:
(1) sex, (2) age of the patients (under/over
60 years), (3) principal diagnosis.
▸ The number of patient treated per year. To calculate
the number of patients, we considered one treatment
per person per year, regardless of the number of epi-
sodes of care (number of treatments) that occurred in
each year.
▸ The yearly rates of hospital episodes per 100 000
population ((number of episodes per year/annual
average resident population per year)×100 000).
▸ The age-standardised rates of hospital episodes per
100 000 population by counties per year ((number of
episodes by county and year/annual average resident
population per county and year)×100 000) using
general demographic information published by
Statistics Portugal.27 County of residence was
obtained from the administrative database used in
the study. We used the direct method of standardisa-
tion as described by Beaghole et al28 for standard
Portuguese population. The age standardisation was
necessary to control the effect of age heterogeneity
across populations living in different counties.
Mainland Portugal is divided into 248 counties that
correspond to local prefectures with specific adminis-
trative and political competences defined by the
central government.
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Study analysis
We first evaluated the diffusion of treatments across
areas using the mean, minimum and maximum values
of the rates of hospital episodes per 100 000 population
in 2002, 2006 and 2012. The relative variation coefficient
was used to measure the dispersion of the diffusion.
Three time points were selected because these corre-
sponded to: 2002—the first year included in this study,
2006—the year before the approval of intravitreal injec-
tions with anti-VEGF by EMA, and 2012 because it was
the latest available information when this study started.
To investigate the determinants of geographical
diffusion of anti-VEGF treatments we used generalised
linear modelling. Considering the longitudinal nature of
the data and its non-normal distribution, we used gener-
alised estimating equations (GEE).29 The dependent
variable was defined as the yearly rate of hospital epi-
sodes per county per 100 000 population. We defined as
independent variables: (1) the years during which the
geographical diffusion was analysed (a linear trend); (2)
a dichotomous variable to indicate the year when the
drug was authorised in the European Union by EMA
(anti-VEGF therapy availability: 0-not available; 1–avail-
able); (3) a dichotomous variable to indicate the avail-
ability of an ophthalmology department in the hospital
of the patient’s county of residence (Ophthalmology
department availability: 0-no ophthalmology depart-
ment; 1–ophthalmology department), and (4) popula-
tion density (population per km2) in the county.
Information about the availability of ophthalmology
departments was obtained in October 2014 from the
Health Ministry official website.30 The referral pathway
for ophthalmology starts with the general practitioner
(GP) according to the local referral guidelines. The
circuit of the treatment does not interfere with our cal-
culations because we compute treatment ratios based in
the country of origin of the patient and this is independ-
ent of the hospital where treatment was administered.
The model was defined as γ log link distribution regres-
sion model as the rate was expected to be positively
skewed with an autoregressive first order matrix repre-
senting time dependence within the repeated subject.31
A total of 278 counties were considered as ‘subjects’ with
repeated measures. Year and dichotomous variable
‘anti-VEGF availability’ were defined as within-subject
independent variables. Dichotomous variable
‘Ophthalmology department availability’ and ‘popula-
tion density rates’ were defined as between-subject vari-
ables. The analysis was performed using IBM SPSS
Statistics V.21.0.
RESULTS
The final sample included 98 408 hospital episodes.
Figure 1 shows that the total number of episodes
increased from 1815 in 2002 to 25 106 in 2012. This cor-
responds to a mean annual increase of 32%.
In 2012, the number of treated patients was six times
higher than in 2002, corresponding to a mean annual
increase of 24%. The ratio number of episodes/number
of patients was 1.16 in 2002, 1.17 in 2006 and 2.1 in
2012. The most relevant demographic information was
the percentage of patients treated who were older than
60 years of age. The figures changed from about 60% in
2002 to 80% in 2012.
Figure 2 shows the five principal diagnoses responsible
for the episodes detected. The figure is expected to
provide a picture of the growth of the number of epi-
sodes per year and number of patients treated per diag-
nosis. The most common diagnosis was exudative AMD,
followed by diabetic macular oedema (diabetes with
ophthalmic complications), oedema of the retina,
retinal neovascularization and non-specific AMD. The
cumulative percentage of episodes associated with these
five diagnoses was 73% in 2012, in contrast with only
16% in 2002. These values corresponded to an increase
Figure 1 Annual number of
hospital episodes of antivascular
endothelial growth factor (anti-
VEGF) treatments and annual
number of treated patients from
2002 to 2012.
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in the yearly rates of hospital episodes per 100 000 indi-
viduals from 17.4 in 2002 to 238.77 in 2012.
Table 1 gives a summary of the mean, minimum and
maximum values in three specific years of the rates of
hospital episodes per 100 000 population. Both
maximum and minimum rate values increased over
time. The relative variation coefficient varied from 200%
in 2002, to 204% in 2006 and 209% in 2012. The relative
coefficient of variation indicates that rates per county
have a great dispersion and that this dispersion did not
reduce over time. The first quintile always contains rates
equal to zero, which means that there are counties
without events. In 2002, there were 58 counties in the
first quintile (without episodes). The number of coun-
ties without episodes reduced over time to 33 in 2006
and 3 in 2012. All the mean values per quintile rose in
the period analysed.
Results of the regression analysis are summarised in
table 2. In agreement with the initial prediction and
consistent with the introduction of the new treatment
with anti-VEGF, the model shows a significant effect of
the variable ‘year’, p<0.0001. For each additional year,
the rate of hospital episodes increased by 28%. The rate
was significantly higher after the EMA approval; table 2
shows results for ‘anti-VEGF therapy availability’,
p<0.0001. With the approval of this treatment, the rates
of hospital episodes increased by 27%. The availability
of an ophthalmology department in the hospital of the
county (in table 2, results for ‘Ophthalmology depart-
ment availability’) significantly increased the rates of
hospital episodes by 243%, p<0.0001 (compared with
counties without). The positive association between the
variable ‘Ophthalmology department availability’ and
our dependent variable indicates that anti-VEGF treat-
ments were more frequent for patients living near hospi-
tals with ophthalmology departments, which are typically
located in areas of median/high population density.
There was a positive association between the dependent
variable and population density. An increase of 100
persons per km2 raised the rates of hospital episodes by
11%. This results show that patients living in rural areas
were less frequently treated.
DISCUSSION
With this study, we wanted to investigate the diffusion of
anti-VEGF treatments for eye disease in Portugal looking
for possible determinates and/or barriers. We per-
formed this investigation by characterising the temporal
and geographical distribution of anti-VEGF treatments
Figure 2 Number of hospital
episodes associated with the top
five diagnoses by year.
Table 1 Age-standardised rates of hospital episodes per 100 000 populations per county in the year 2002, 2006 and 2012
Quintile
2002 2006 2012
Mean Minimum Maximum Mean Minimum Maximum Mean Minimum Maximum
1st 0 0 0 0.0001 0 0.0002 0.0013 0 0.0024
2nd 0.0002 0.0001 0.0003 0.0003 0.0002 0.0005 0.0037 0.0024 0.0051
3rd 0.0005 0.0004 0.0008 0.0009 0.0006 0.0013 0.0069 0.0051 0.0091
4th 0.0012 0.0008 0.0017 0.0019 0.0013 0.0026 0.0148 0.0093 0.0221
5th 0.0048 0.0017 0.0231 0.008 0.0026 0.0459 0.0764 0.0222 0.3745
Total 0.0013 0 0.0231 0.0022 0 0.0459 0.0208 0 0.3745
Values show quintiles mean, minimum and maximum values.
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using codes for specific type of procedures from all epi-
sodes performed in public hospitals. Our results show
that the number of episodes for the codes analysed was
low before the introduction of anti-VEGF treatments.
The numbers of episodes rose significantly since the
treatment was introduced in the country in 2007. The
most relevant finding was that patients from small areas
without ophthalmology departments near their resi-
dence received fewer treatments as revealed by the geo-
graphical distribution of episodes. The unequal
distribution is puzzling, given the equity-oriented nature
of the Portuguese NHS.
We consider three possible barriers for the equitable
anti-VEGF diffusion related to legal, technical and finan-
cial factors. Following the EMA approval of this treat-
ment in 2007 and the NHS coverage decision in 2008,
the treatment became legally available at all ophthalmol-
ogy departments in Portugal. One can thus say that the
legal problem was sorted out. However, technical condi-
tions were imposed for the use of this treatment that
included extra training for doctors and that the proced-
ure needed to be performed in the operation theatre.18
These technical requirements possibly created financial
and service capacity pressures on ophthalmology depart-
ments.1 4 Indeed, higher rates of treatment were
observed mostly in areas around big cities and specia-
lised centres. Smaller hospitals may have taken longer to
adopt this treatment due to budget limitations or tech-
nical conditions. It should also be mentioned that
anti-VEGF therapy was first introduced to treat AMD,
and then expanded to diabetic macular oedema and
central retinal vein occlusion treatment. This certainly
increased the rate of hospital episodes, but the effect is
expected to be similar in all counties.
Regarding financial barriers, we can speculate about
two main budget limitations that reduced the speed of
diffusion of anti-VEGF treatments. The first financial
challenge is the cost of the treatment of approximately
€1913 per episode, a figure similar to the USA.25 32 In
Portugal, hospitals receive a global budget from the gov-
ernment that covers the cost of all drugs and medical
devices.18 During the period included in this study, the
financing methodology used to allocate resources to the
Portuguese NHS hospitals has been subject to several
changes. This included the introduction of different
unit payments and new incentive programmes that rely
on quality and cost indicators. These changes to hospital
budgets and pressure for cost containment may have
reduced the availability of anti-VEGF treatments in small
hospitals, concentrating patients in big centres with
limited capacity. A second financial barrier for hospitals
is the fact that the intravitreal injections need to be
administered in an operating room by an ophthalmolo-
gist. Typically, patients receive three injections in the
first 3 months, followed by monthly visits for assessment
and further injections, as necessary.22 These surgical
procedures and monthly appointments impose high
demands on hospitals (staff and facilities). In a period
of tight budgets, expansions in the medical staff or facil-
ities are difficult to implement; these problems have
been recently reported by Marko Hawlina, a retinal spe-
cialist form Slovenia, quoting results of a survey of the
European Union of Medical Specialists.33 Thus, some
hospitals may have delayed the start of these treatments
or these may still not be available.
The reasons outlined above have implications for the
geographical diffusion of the treatment leading to
inequalities. Patients referred from distant cities or rural
areas may have delayed access to treatments. The lower
rate of treatments for patients living in areas of low
population density may also indicate that these patients
are more likely to miss follow-up appointments.
Travelling distances may be a barrier to attending
appointments as reported by other studies.34–36 These
findings are causes of concern because lost vision
caused by eye diseases for which anti-VEGF treatments
are indicated cannot be restored. That is, reduced
number of treatments might lead to an increased
number of people becoming permanently visually
impaired due to treatable causes.
During this study we found some limitations: the lack
of specific codes for anti-VEGF injections, the inability to
Table 2 Results of the Generalised Estimating Equation for the rate of hospital episodes per 100 000 population per year
and independent variables were: year, anti-VEGF therapy availability (separating years before and after the drug was
authorised by EMEA); Ophthalmology department availability (representing the availability of ophthalmology departments in
the hospitals of county of residence), and population density (population per km2 in the county).
Parameter IRR* p Value
95% CI†
Lower Upper
Year (from 2002 to 2012) 1.281 <0.001 1.263 1.299
Anti-VEGF therapy availability (0—not available; 1—available) 1.270 <0.001 1.183 1.362
Ophthalmology department availability (0—no ophthalmology department;
1—ophthalmology department)
3.430 <0.001 2.566 4.583
Density rate (per 100 persons) 1.113 <0.001 1.095 1.132
Total number of counties is 278.
*Incidence Rate Ratio.
†Wald χ2 test of significance (95% CI).
antivascular endothelial growth factor (anti-VEGF)
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follow patients across different years, the exclusion of the
activity in the private sector and the absence of individual
data. Limitations caused by non-specific codes have been
described in methods. The inability to follow patients
across years might have had an impact on the ratio of epi-
sodes/patient that we found. Nevertheless, the county of
residence remained unchanged across years ensuring
temporal and geographical accuracy of treatment diffu-
sion. Other studies analysing equivalent temporal periods
also report treatment ratios under 3 per year. These
authors explained the low ratios by a higher concentra-
tion of patients treated as required.1 Numbers from
private treatments were likely to be small because this
treatment is expensive and patients tend to look for care
in the National Health System where treatment is almost
free. The lack of individual data limited our analysis of
socioeconomic determinants, such as patient income or
education level or other clinical conditions that could
restrict the prescription of anti-VEGF therapy. However,
with the available data we were able to construct a
complex and multivariable model to explain the geo-
graphical diffusion and time variation based on a nation-
ally representative database with many types of hospital
settings and geographic areas; this would have been diffi-
cult to perform with a limited sample number of cases.
In brief, the use of anti-VEGF drugs in ophthalmology
marked the beginning of effective treatments for
age-related eye diseases that can lead to severe visual
impairment. This study shows that the number of intravi-
treal procedures increased substantially since anti-VEGF
treatments were approved in Portugal, but that the diffu-
sion was inequitably distributed. Local restrictions to the
temporal and geographical diffusion seem mostly
imposed by financial aspects. These financial constraints
may arise not only from cuts in budgets in the health-
care system but also from difficulties for families to fund
travel costs. With the ageing of the population and the
expected growth in conditions, such as diabetic retinop-
athy and age-related macular degeneration, the demand
for these treatments is likely to increase.7 The combin-
ation of these factors will maintain pressure on ophthal-
mology departments delivering eye care. Health
authorities need to consider equitable distribution when
planning human and material resources for ophthalmol-
ogy departments.
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